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temozolomide in monotherapy 150mg/m2/D1–5 (1st cycle) and 200mg/m2/D1–5 ending in December 2009. Currently has
headaches that disappear with analgesia, with no signs of recurrence in serial MRI. Progression-free interval > 3 years.
Discussion. First described in 1895, is a variant of glioblastoma multiforme (2–8%) with a glial and a sarcomatous component.
With peak incidence between 50-70 years, male: female ratio of 1.4:1 and most common in the temporal lobe. The sarcomatous
component can metastasize (15-30%, more than the glioblastoma multiforme) more frequently to spinal cord, lung, bone and
lymph nodes and surrounding structures. The glial usually corresponds to glioblastoma, although sometimes described oligo-
dendrogliomas or subependymomas. The survival ranges from 8 to 24 months. Rarely occur as multicentric tumors. Factors
affecting overall survival are age at presentation, extent of resection, adjuvant radiotherapy and race, has been that men have
more survival and tumor size also has an impact at this level.
Conclusions. It is a rare tumor with a worse prognosis than glioblastoma multiforme, where a good surgical and adjuvant therapy
with RTE+QT is a determining factor in overall survival.
http://dx.doi.org/10.1016/j.rpor.2013.03.156
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Granulocytic sarcoma (GS) is an uncommon extramedullary tumor composed of dense aggregates of immaturemyeloid precursor
cells, which is usually associated with acute or chronic myeloid leukemia. The tumor may also be a predecessor to acute myeloid
leukemia (AML). It may be found in any location throughout the body; however, intraoral occurrence is extremely rare. Radiation
therapy is often used in the treatment of chloromas, we reviewed one case to analyze treatment response, disease control and
toxicity associated with RT. Our patient is a 61 year old woman was diagnosed in 2007 of breast carcinoma which was treated with
chemotherapy: secondary of this treatment, the patient developed an AML in March 2010.PETHEMA protocol is included in 2007
and is administered LAM induction IDA-ARAC. Autotransplant performed in 2011. Few months ago, complained of pain in right
jaw so it is sampled with a diagnosis of mandibular granulocytic sarcoma, in the analyzed sample objective decline granulocytic
series and blast population (60%) and aberrant expression of CD7, so it was decided to administer RT dose of 30Gy in 15 fractions
with concomitant chemotherapy. Patients are most often referred for RT for chloromas at recurrence or progression although
radiation might have a role in other cases, a low dose of radiation (30Gy in 15 fx) can be applied with excellent disease control
and combinated modality therapy is warranted.
http://dx.doi.org/10.1016/j.rpor.2013.03.157
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The midline angiocentric lymphoma (also known as lethal midline granuloma) is a rare lymphoid neoplasm, with an often-
difﬁcult diagnosis due to the non-speciﬁc symptoms. This lymphoma is an aggressive Non-Hodgkin’s (NHL) type, which is
normally found in the upper respiratory tract (often in the nasal cavity), and has a bad prognosis, as the average survival rate is
between 12 and 18 months, without treatment. It is predominantly found in patients who are between 50 and 60 years old and
with a slight tendency towards males. Case report: At September 1995, Spanish male patient (59 years old) was referred to Oto-
laringology Department with fever, purulent rhinorrhea, headache, weight loss and nasal respiratory obstruction. Polypectomy
was performed at January of 1996; it was found histologically that the patient had a lethal midline granuloma. CT revealed a mass
encroaching on the right frontal sinus, maxillary sinus and nostril to nasopharynx. He received chemotherapy and radiotherapy
(40Gy on ethmoid and maxillary sinuses and 10Gy on nasals and ethmoid sinuses) treatments were successful and lesion had
disappeared. Currently, sixteen years later, our patient is still alive without any kind of symptoms.
http://dx.doi.org/10.1016/j.rpor.2013.03.161
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Introduction. The anaplasic astrocytoma (AA) is included as a grade III glioma in the OMS classiﬁcation. The patients with AA
have a median of survival of 17–24 months after the diagnosis. Inside the prognosis factors, it is included: age, mental state at
the diagnosis and the general state (PS). The standard treatment is based on surgery (maximum possible resection), followed by
postoperative radiotherapy (RT). The use of adjuvant chemotherapy (QT) is controversial in the AA. The amount of exeresis has
been linked with the increase of patients survival.
Case report. Male patient, of 55 years old, who after a traumatic brain injury with loss of consciousness is diagnosed by brain
MRI a deep temporal intra-axial expansive lesion with left lenticulocapsular caudal participation of about 4.5 cm in maximum
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diameter. A stereotactic biopsy is made and the AA is diagnosed. Surgery is dismissed because of eloquent areas commitment.
STUPP scheme starts: RT, 60Gy, 200 cGy/fraction over tumor volume+margin and temozolomide (TMZ) (75mg/m2) concurrent
and adjuvant. After the ﬁrst appreciation of the treatment response by brain MRI, the partial response of the lesson is objective
with reduction of more than the 50% of its volume. Nowadays, he has 48 months of tracing and 46 cycles of adjuvant TMZ, with
lesson stabilization. He has presented toxicity at CNS level grade I and gastrointestinal levels I and II (according the RTOG grades).
Conclusion. The role of adjuvant QT in this type of tumor is not well deﬁned, if no signiﬁcant toxicity, might consider prolonging
administration if such cycle thereby maintaining the stabilization of the tumor. It would be necessary to conduct studies that
could prove this hypothesis.
http://dx.doi.org/10.1016/j.rpor.2013.03.162
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Summary. 48 year old male patient diagnosed of nasopharyngeal squamous carcinoma poorly differentiated stage IV for bone and
liver involvement, MIB 40%, positive for EBV by EBER, AE1-AE3 panqueratinas, 1, 10, 5 and 14 keratines. Treatment was started
with concurrent RT (DT: 70Gy) and cisplatin 75mg/m2 on September 23, 2010. At the end of treatment he showed a complete
metabolic radiological response of primary tumor, and partial response of bone lesions by PET CT. He continued treatment with
palliative cisplatin (60mg/m2 D1/28)/5 FU (800mg/m2 D1–5/28d ic), receiving 8 cycles, and getting stable disease until September
2011, when made clear important lung, bone and liver progression. He referred important dorsal pain poorly controlled with
analgesic for what was planned a new palliative RT treatment on D7–D10. New treatment was began on October 5, 2011 with
cetuximab (250mg/m2/sem)/taxol (80mg/m2/sem) weekly getting partial response in lung, liver and bone paradoxical response
with clear clinical beneﬁt, without NRL symptoms. In April 2012 new liver and bone progression appears so we started treatment
with gemcitabine 800mg/m2 every 14 days and zoledronic acid. In August 2012 new progression, initiating treatment with
intravenous methotrexate 30mg/m2 weekly. He introduced worse irradiated lumbosacral pain so we increased opioid treatment
with MST until 40mg/12h without improvement and visualizing total sacro occupying lesion, new treatment is planned on sacral
with RT DT 30Gy. In November 2012 new progression at multiple levels, he was treated with vinorelbine (25mg/m2 D1, 8/21) in
compassionate use. He died on 31/12/12. Approximate median survival of nasopharyngeal carcinoma st IV of 10 months.
Patient survival. 26 months.
http://dx.doi.org/10.1016/j.rpor.2013.03.163
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Summary. 68 year old male patient with severe COPD managed with oxygen therapy, who initiated progressive dysphagia for
solids in March 2007. Digestive endoscopy was performed ﬁnding a medium esophageal tumor with positive biopsy for squamous
carcinoma. TAC extension study visualized a mass in the middle third of the esophagus, 7 cm length and adjacent pathological
adenopathywithout distance involvement. Considering it inoperable for a high anesthetic risk,we startedQT treatment (cisplatin
– 5 FU) and concurrent RT 3D over an esophageal tumor volume and nodal chains, total dose of 45Gy (5×180 cGy) concluding on
July 2007. Adjuvant QT is completed until September 2007 Excellent treatment tolerance improving the dysphagia progressively.
The digestive endoscopy after treatment viewed mass persistence so we performed two sessions with Ir 192 brachytherapy
(5Gy) Evolution: On April 29, 2008, we objectiﬁed two brain metastases managed RT holocraneal, DT: 32.5Gy (13×250 cGy) and
subsequent radiosurgery on both lesions administered 15Gy to isodose of 85% in September 2008. Without ﬁnding disease
progression in successive controls. Since July 2012 the patient presented progressive deterioration with episodes of dizziness,
nausea and instability, TAC is performed on August 2012 ﬁnding important perilesional edema, initiating oral corticosteroids
treatment with progressive improvement. He has requested steroid treatment with intermittent pattern with signiﬁcant side
effects (muscle atrophy, irritability, hypertension) being impossible the total removal for NRL progressive deterioration Current
status: In January 2013 a RM was done, coming upon right temporal radionecrosis. Due to the dependence to corticosteroid
treatment and severe side effects we start bevacizumab in compassionate use. Disease-free interval 4 years from diagnosis of
brain metastases.
http://dx.doi.org/10.1016/j.rpor.2013.03.164
